In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ian Haydock

Tokyo, Japan
Ian is head of pharma news content for the Asia-Pacific area and has been covering the region for more than 20 years as an editor for Scrip and more recently as managing editor of PharmAsia News. He has a long background in Asia, having grown up in Hong Kong, and a particular interest in regional regulatory harmonization and trade initiatives and the development of the Japanese pharma sector. Ian lives in Tokyo with his wife and two sons.

Latest From Ian Haydock

Asia Deal Watch: CANbridge Licenses Orphan Disease Candidates From Mirum, LogicBio

US-based, China-focused CANbridge moves into cholestatic liver disease and enzyme replacement therapy via two deals. Plus deals involving LegoChem, TransThera, Morepen, Daiichi Sankyo, Geneseeq, Innocare, Biosplice, Sirnaomics and Walvax.

Deals Business Strategies

Quick Listen: Scrip’s Five Must-Know Things

In this week's podcast version of Five Must-Know Things, hear about possible new life for Tecfidera, activist investors and GSK, a new mRNA vaccine in Europe, diversity in clinical trials, and a look at last year’s drug launches.

Coronavirus COVID-19 Vaccines

Deal Watch: Gain To Test Enzyme-Enhancement Tech In Cancer With Zentalis

Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.

Deals Business Strategies

Quick Listen: Scrip’s Five Must-Know Things

In this week's podcast version of Five Must-Know Things, hear about adenovirus vaccines and blood clots, Lilly’s new moves in genetic diseases, the efficacy debate over Chinese COVID-19 vaccines, putting a price tag on innovation, and Sanofi’s bullishness on IL-2.

Research & Development Vaccines

Sanofi Goes Big On Asia Vaccines With Singapore Investment

French giant makes its biggest single investment to date in Asia as it prepares to build up regional vaccine production capacity, in part to help prepare for future pandemics. 

Singapore Manufacturing

Quick Listen: Scrip’s Five Must-Know Things

In this week's podcast version of Five Must-Know Things, hear about whether safety concerns may affect JAK inhibitors, Takeda’s strategic R&D plans, Cigna’s psoriasis insurance program, Phase III readouts to look for, and an overview of the global pharma R&D pipeline.

Commercial Coronavirus COVID-19
See All
UsernamePublicRestriction

Register